How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase
Collagenases
Intralesional injections
Penile induration
Peyronie's disease
Therapeutics
Journal
The world journal of men's health
ISSN: 2287-4208
Titre abrégé: World J Mens Health
Pays: Korea (South)
ID NLM: 101596899
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
21
02
2019
revised:
08
04
2019
accepted:
28
04
2019
pubmed:
14
6
2019
medline:
14
6
2019
entrez:
14
6
2019
Statut:
ppublish
Résumé
The aim of this study was to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) in patients with Peyronie's disease (PD) suffering from atypical deformities. We retrospectively collected data of patients with atypical penile curvature (PC) secondary to PD. All patients underwent a modified treatment protocol, consisting of 3 intralesional injections of 0.9 mg of CCH performed at 4-week intervals at the point of maximum PC. Patients were instructed to follow a strict routine, involving daily modeling of erect penis and stretching at the urinary toilette time, two minutes each. Success was defined as a decrease in PC of ≥20° from baseline. Sixty-five patients were included in the analysis. Median age was 59.0 years (interquartile range [IQR], 53.0 to 63.0 years), median curvature 40.0° (IQR, 30.0° to 45.0°) median duration of the disease 12.0 years (IQR, 6.5 to 24.0 years). Fifty-three patients (81.54%) had ventral PC, 7 (10.77%) hourglass PC, and 5 (7.69%) shortening PC. Median changes of PC were -20.0 (IQR, -20.0 to -10.0; p<0.01) in ventral PC, -20.0 (IQR, -20.0 to 0; p<0.01) in hourglass and -15.0 (IQR, -15.0 to -15.0; p<0.01) in shortening PC. At Kruscal-Wallis test, significant differences between groups were not found. The rate of PC success was 56.60% (30/53) in ventral PC, 57.14% (4/7) in hourglass and 20.00% (1/5) in shortening PC (p=0.29). Treatment success was not influenced by characteristics of curvature (odds ratio=0.66; p=0.20). CCH intralesional injections could represent an effective therapeutic option for the conservative management of patients with atypical PC.
Identifiants
pubmed: 31190485
pii: 37.e28
doi: 10.5534/wjmh.190026
pmc: PMC6920074
doi:
Types de publication
Journal Article
Langues
eng
Pagination
78-84Informations de copyright
Copyright © 2020 Korean Society for Sexual Medicine and Andrology.
Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
J Sex Med. 2011 Dec;8(12):3446-51
pubmed: 21981553
J Sex Med. 2018 Oct;15(10):1472-1477
pubmed: 30245025
BJU Int. 2010 Oct;106(8):1178-80
pubmed: 20438558
Sex Med Rev. 2019 Apr;7(2):338-348
pubmed: 29631979
J Urol. 1993 Jan;149(1):56-8
pubmed: 8417217
J Urol. 2013 Jul;190(1):199-207
pubmed: 23376148
Biochemistry. 1987 Feb 10;26(3):681-7
pubmed: 3032235
J Sex Med. 2018 May;15(5):716-721
pubmed: 29699756
J Sex Med. 2015 Apr;12(4):1072-9
pubmed: 25664497
Urology. 2017 Jun;104:102-109
pubmed: 28347795
J Sex Med. 2017 Nov;14(11):1430-1437
pubmed: 28974406
J Sex Med. 2016 Jun;13(6):905-23
pubmed: 27215686
J Urol. 1985 Aug;134(2):280-3
pubmed: 2991611
J Sex Med. 2015 Dec;12(12):2492-8
pubmed: 26646187
J Urol. 2015 Dec;194(6):1704-7
pubmed: 26144333
J Sex Med. 2015 Jan;12(1):248-58
pubmed: 25388099
BJU Int. 2018 Oct;122(4):680-687
pubmed: 29791971
Sex Med Rev. 2017 Apr;5(2):211-221
pubmed: 27544298
BJU Int. 2017 Nov;120(5):717-723
pubmed: 28612401
Urol Res. 1982;10(3):135-40
pubmed: 6291216
J Urol. 2015 Sep;194(3):745-53
pubmed: 26066402
J Sex Med. 2008 Aug;5(8):1977-84
pubmed: 18564146
J Sex Med. 2013 Mar;10(3):653-60
pubmed: 23153101
J Sex Med. 2008 Jan;5(1):180-7
pubmed: 18173766
Urology. 1997 Jun;49(6):822-30
pubmed: 9187685
Andrology. 2018 Jul;6(4):564-567
pubmed: 29733116
J Sex Med. 2007 Nov;4(6):1527-38
pubmed: 17970969